A Phase 2a, Double-blind, Randomized, Placebo-controlled, Repeated Administration, Crossover Study to Establish Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects

Trial Profile

A Phase 2a, Double-blind, Randomized, Placebo-controlled, Repeated Administration, Crossover Study to Establish Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Presbidrops (Primary)
  • Indications Presbyopia
  • Focus Therapeutic Use
  • Sponsors Orasis Pharmaceuticals
  • Most Recent Events

    • 31 Jul 2017 Status changed from recruiting to completed.
    • 19 Mar 2017 Planned End Date changed from 1 Oct 2016 to 1 Jul 2017.
    • 19 Mar 2017 Planned primary completion date changed from 1 Aug 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top